Floatz logo

Deferasirox

Recurrent Ovarian Germ Cell Tumor

City of Hope Medical CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Ovarian Germ Cell Tumor cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Nabil Adra
Phase 3BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Carboplatin
Case Comprehensive Cancer Center
Phase 2BB
BLEOMYCIN
Children's Oncology Group
Phase 3BB
Metformin
University of Chicago
Phase 2BB

View all 44 →

Same molecule, other indications

Deferasirox is also rated in:

iron poisoningDormant
A
Indicative ·
82 / 100
View asset →
hemosiderosisDormant
A
Indicative ·
81 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →